Product Information
DOFETILIDE 250 MCG CAPSULE is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1938 per EA under NDC 59651011960. Its NADAC has been published 379 times since Jul 3, 2019.
FDA first approved this application on Jan 22, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.25 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
59651011960
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOFETILIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210740FDA Approved
1/22/2019
TE Code
AB
On Market Since
1/22/2019
Pharmacological Classes
Price Statistics
The NADAC for DOFETILIDE 250 MCG CAPSULE has been published 379 times since Jul 3, 2019, and over the history we have for it it has declined 93.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1938 per EA |
|---|---|
| All-time high | $3.1650 (Jul 10, 2019) |
| All-time low | $0.1886 (Feb 18, 2026) |
| 52-week high | $0.2171 |
| 52-week low | $0.1886 |
| Median price | $0.6840 |
| Average price | $0.8717 |
| Largest weekly change | +51.6% (Aug 17, 2022) |
| Weeks tracked | 379 |
| Tracking since | Jul 3, 2019 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dofetilide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOFETILIDE 250 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DOFETILIDE 250 MCG CAPSULE, manufactured by Aurobindo Pharma Limited, is $0.1938 per EA (NDC 59651011960), effective Sep 30, 2026.
How has the price of DOFETILIDE 250 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for DOFETILIDE 250 MCG CAPSULE has declined 93.9%. It has been tracked across 379 weekly CMS publications since Jul 3, 2019.
What are the highest and lowest recorded NADAC prices for DOFETILIDE 250 MCG CAPSULE?
Since Jul 3, 2019, the NADAC for DOFETILIDE 250 MCG CAPSULE has ranged from a low of $0.1886 (Feb 18, 2026) to a high of $3.1650 (Jul 10, 2019), with a median of $0.6840 per EA.
Are there cheaper alternatives to DOFETILIDE 250 MCG CAPSULE?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DOFETILIDE 250 MCG CAPSULE, is $0.1886 per EA — about 3% below DOFETILIDE 250 MCG CAPSULE.
Who manufactures DOFETILIDE 250 MCG CAPSULE?
DOFETILIDE 250 MCG CAPSULE (NDC 59651011960) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.